41 years ago this month my patient was diagnosed with HIV. At that time he was nineteen years old and medicine was only learning about the devastation of HIV. 41 years ago there wasn’t any treatment for HIV. The first medication we had to treat HIV was AZT or zidovudine, which wasn’t approved until 1987. We don’t use AZT anymore because of the severe side effects it had, including bone marrow suppression, lactic acidosis and liver damage.
As an intern at Jersey City Medical Center, HIV/AIDs patients would take AZT five times a day and we would then give them blood transfusions periodically to address the severe anemia caused by AZT. By the time I became an attending in infectious disease, all we had added were Epivir and Zerit to our arsenal. It was also the time of what I called the slow retreat. As patients’ T-cell counts continued to drop, the infections they would incur became more exotic. Bactrim was effective against PCP and toxoplasmosis. Diflucan was effective against cryptococcus.
Before we had Diflucan we would give patients a dose of Amphotericin B, affectionately known as Amphoterrible B, because of the side effects, once a month, because that’s all we had.
By the time I was attending physician at St. Claire’s Hospital, the largest designated HIV center in New York City, I won the nickname, Bottom Gun, a play on Top Gun. Where Top Gun was the best of the best, I had the worst of the worst. Not that my patients were bad people, no, many of them were some of the nicest people you can imagine. They were the worst because they had very few T-cells left. One patient named his after the Marx Brothers, because he only had four. Another after the Three Stooges. Twenty points if you can name all four Marx Brothers and all six Stooges.
With so few T-cells the infections became less treatable. The most severe illness I remember had to be CMV meningitis. It was severe because even with aggressive therapy, mortality was close to 100%. This is what I mean by the slow retreat.
Thirty years ago when I moved to Atlanta, is when I met my patient. He was in the hospital with PCP pneumocystis carini pneumonia. A pneumonia that affects people with extremely poor immune systems. By that time, we were able to measure viral activity in the body which was a monumental breakthrough, because we could now measure how effective our antiviral therapy was.
It was also the time where we had more medications to help combat HIV. The introduction of protease inhibitors helped in treating HIV. It was life saving, but the PIs also carried some nasty side effects. One in particular was avascular necrosis of the femoral head and several of my patients wound up having total hip replacements because of PI use. For those patients, however, the trade off was worth it. Another serious problem associated with PIs was an increase in cardiovascular disease.
Thankfully we have been able to move away from PIs and use other medications like integrase inhibitors to treat HIV with minimal side effects. Now it looks like for some patients we are able to move away from triple medication therapy to two medications. Do I use this in some of my more stable patients? Yes, but if I learned one thing in dealing with HIV, it is watch and wait.
Regardless, as my patient and I celebrate his anniversary, I am still amazed at how far we came in the past forty years, but we still have a long way to go.